Humacyte (HUMA) said Wednesday that it has sold its first sale of Symvess to a US military treatment facility serving around 200,000 active-duty personnel, retirees, and their families.
The company said the sale follows Symvess's recent listing on the US Defense Logistics Agency's ECAT system, enabling its access across 35 military treatment facilities and 160 US Department of Veterans Affairs hospitals.
Symvess received US FDA approval for treating extremity vascular trauma in December.
Shares of the company were up more than 7% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.